相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (vol 5, 17499, 2015)
Niki Karachaliou et al.
SCIENTIFIC REPORTS (2023)
Cancer statistics, 2023
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2023)
Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression
Phyllis F. Cheung et al.
Nature Communications (2022)
Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer
Tina Cascone et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2022)
Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: The role of phosphodiesterase 4
Ewa Kolosionek et al.
MOLECULAR BIOLOGY OF THE CELL (2022)
MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF
Xin Wang et al.
CELL DEATH AND DIFFERENTIATION (2021)
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
Sylvie Lantuejoul et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Tumor organoid-T-cell coculture systems
Chiara M. Cattaneo et al.
NATURE PROTOCOLS (2020)
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
Carol M. Amato et al.
CANCERS (2020)
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S. Grasso et al.
CANCER CELL (2020)
CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8+T cells via NF-κB signaling
Ben-Shun Hu et al.
CANCER CELL INTERNATIONAL (2020)
STK3 Suppresses Ovarian Cancer Progression by Activating NF-κB Signaling to Recruit CD8+ T-Cells
Xiangyu Wang et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2020)
IL-4 together with IL-1β induces antitumor Th9 cell differentiation in the absence of TGF-β signaling
Gang Xue et al.
NATURE COMMUNICATIONS (2019)
TNF-α enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways
Yuxue Jiang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Martin Reck et al.
EUROPEAN JOURNAL OF CANCER (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors
Yong Lu et al.
CANCER CELL (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids
Krijn K. Dijkstra et al.
CELL (2018)
NF-κB, inflammation, immunity and cancer: coming of age
Koji Taniguchi et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives
Lazaros I. Sakkas et al.
CURRENT MEDICINAL CHEMISTRY (2017)
The phosphodiesterase 4 inhibitor roflumilast augments the Th17-promoting capability of dendritic cells by enhancing IL-23 production, and impairs their T cell stimulatory activity due to elevated IL-10
Matthias Bros et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PGE2 Elevates IL-23 Production in Human Dendritic Cells via a cAMP Dependent Pathway
Quanxing Shi et al.
MEDIATORS OF INFLAMMATION (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The development and in vivo function of T helper 9 cells
Mark H. Kaplan et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1-Driven Regulation of cAMP Phosphodiesterase-4D
Ningning He et al.
MOLECULAR CANCER THERAPEUTICS (2014)
NF-κB control of T cell development
Steve Gerondalds et al.
NATURE IMMUNOLOGY (2014)
Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF
S. S. Pullamsetti et al.
ONCOGENE (2013)
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers
De-Chen Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Th9 cells promote antitumor immune responses in vivo
Yong Lu et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
IL-12 and IL-23 Affect Photocarcinogenesis Differently
Christian Jantschitsch et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis
Michele W. L. Teng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Whole tumor antigen vaccines
Cheryl Lai-Lai Chiang et al.
SEMINARS IN IMMUNOLOGY (2010)
IL-23 promotes tumour incidence and growth
John L. Langowski et al.
NATURE (2006)
STAT3 and NF-κB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice
Mi-La Cho et al.
JOURNAL OF IMMUNOLOGY (2006)
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
H Park et al.
NATURE IMMUNOLOGY (2005)
Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway
M Schnurr et al.
BLOOD (2005)
Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells
AF Sheibanie et al.
FASEB JOURNAL (2004)
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
S Aggarwal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R
C Parham et al.
JOURNAL OF IMMUNOLOGY (2002)
分享论文
